TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient referred to Clinical Physiological/Nuclear Medicine departments for SeHCAT~* Suspected Bile acid diarrhoea~* Age \> 18 years and under 80 years~* women of fertile age must use safe contraception during the treatment part of the study~* Ability to give informed consent after written and oral information in Danish language~Exclusion Criteria:~* Inflammatory bowel disease, including microscopic colitis~* Investigator assessed debilitating chronic disease e.g. World Health Organisation performance score 3-5~* Prior treatment with colesevelam~* Treatment with laxatives or anti-diarrhoeal drugs during the study~  * Except for stable dose the last four weeks of psyllium husk and opioids for pain~* Breastfeeding women~* Crucial medication that cannot be separated appropriately from colesevelam~  * i.e. taken one hour before or 4 hours after colesevelam~* Oral anticoagulation, both warfarin, and new oral anticoagulation~* Treatment with cyclosporine within two months~* Bowel obstruction (subileus or ileus)~* Biliary obstruction~* Short bowel syndrome~* Bowel ostomy~* Allergy to colesevelam or its constituents~* Allergy to placebo constituents (excluding lactose)~* Investigator assessed high risk of non-compliance~* If on statin/fibrate medication, unwilling to pause medication between study visits 1 and 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam, active arm (Type: EXPERIMENTAL): Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days
- Placebo (Type: PLACEBO_COMPARATOR): Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females older than 18 years of age.~* Limb ischemia with ABI of \< 0.7 in the index lower extremity in two consecutive examinations done at least 1 week apart.~* Limb ischemia with resting ischemic pain and/or claudication at 100 meters and/or non-healing ulcers.~* Claudication~* Patients not considered candidates for surgical or percutaneous revascularization, due to poor target vessels, inability to cross total occlusions, or a morbidity which precludes general anesthesia.~Exclusion Criteria:~* Inability to provide informed consent.~* Previous angiogenic therapy.~* Known sensitivity to gentamycin and/or amphotericin B.~* Use or expected use of antineoplastic drugs.~* Any illness, which might affect the patient's survival after enrollment in the protocol.~* Any illness or significant laboratory abnormality, which in the investigator's judgment will interfere with the patient's ability to comply with the protocol, compromise the patient's safety, or interfere with the interpretation of the study results.~* No evidence of acute infection~* WBC \> 15000.~* WBC \< 4000.~* Serum Creatinine \> 3.0 mg/dL in patients who are not in hemodialysis.~* Pregnant women or women planning to become pregnant or unwilling to use appropriate birth control methods before and 2 months after cell infusion.~* Recent myocardial infarction within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MESENDO (Type: EXPERIMENTAL): All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
- placebo (Type: PLACEBO_COMPARATOR): All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Light Treatment Effectiveness (LITE) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide informed consent (age 18+) or parental permission and assent (ages 12-17)~2. Age 12 or older~3. Plaque or guttate psoriasis predominantly located on trunk and/or extremities, with a physician global assessment average of \>1.0, and considered a candidate for phototherapy~4. Patient is deemed willing and able to comply with either in-office or in-home phototherapy:~   1. In office: Able to travel about 3 times per week for 12 weeks from home, work and/or school during business hours of local site~  2. In home: Has space to accommodate home phototherapy unit and patient (or if 12-17, parent), willing and able to follow home phototherapy instructions~5. New or established patient in the practice~Exclusion Criteria:~1. Patients who are judged unable or unwilling to comply with either in office or in home phototherapy due to time, work, school, or other financial constraints~2. Patients judged unable to follow home phototherapy protocol due to failure to demonstrate understanding of the following:~   1. How to operate the phototherapy device~  2. How to follow the dosing protocol~  3. Requirement to wear protective eyewear and genital protection equipment~3. Patients with known history of lack of efficacy to phototherapy or treated with phototherapy 14 days prior to baseline visit~4. Psoriasis predominantly located on scalp, body folds, genitals, palms and/or soles or with a physician global assessment average of ≤ 1.0~5. Patients deemed unsafe to be treated with phototherapy:~   1. History of photosensitivity or autoimmune disease such as lupus or dermatomyositis which can be aggravated by ultraviolet radiation~  2. History of arsenic intake~  3. Unable to tolerate standing for required duration of treatment due to age or physical function~  4. History of melanoma or multiple non-melanoma skin cancers that in the opinion of the principal investigator contraindicates treatment with phototherapy~6. Clinical site deems the participant is ineligible for reason other than eligibility or screening criteria.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Office Based Phototherapy (Type: OTHER): Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
- Home Based Phototherapy (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescent girls 13-21 years old with bone age ≥ 14 years~* Overweight girls: Body Mass Index (BMI) greater than the 95th percentile for age~* Waist/Hip ratio ≥ 0.85~* Insulin Like Growth Factor -1 (IGF-1) below -0.5 standard deviations (SD) for pubertal stage or age~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior to enrollment in the study~* Significant weight gain or loss within 3 months of study (more than 5 kg)~* Use of medications that affect GH or cortisol levels (such as estrogen including oral contraceptive pills, oral glucocorticoids)~* Use of medications such as Meridian and Orlistat~* Presence of diabetes mellitus~* Uncontrolled Thyroid disorders~* Chronic renal insufficiency~* Participation in another simultaneous medical investigation or trial~* Active neoplasm or history of cancer~* Prader-Willi syndrome~* History of scoliosis if bone age is \<15 years~* Hypersensitivity to rhGH or constituents of the injections

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- recombinant human growth hormone (Type: EXPERIMENTAL): Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known or suspected prostate cancer who have been referred to the Department of Radiology at the University of Chicago Medical Center for a diagnostic MRI exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.~* Written informed consent.~Exclusion Criteria:~* Patients incapable of giving informed written consent;~* Patients who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;~* Patients with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.~* Prisoners;~* Minor children (under the age of 18 years old).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional Arm (Type: EXPERIMENTAL): Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be between at least 18 years of age and less than 80 years of age.~* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving intracoronary abciximab and/or aspiration thrombectomy.~* He/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.~* Subject must have evidence of acute ST-segment elevation myocardial infarction with TIMI 0 or 1 flow, or visible thrombi (thrombus grade ≥ 3)~* Target lesion(s) must be located in a native coronary artery in the proximal to mid segment with estimated reference diameter of ≥ 2.5 mm and ≤ 4.0 mm.~* Target lesion(s) must be amenable for percutaneous coronary intervention.~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Abciximab, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)~* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.~* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.~* Baseline hemogram with Hb\<10g/dL or PLT count \<100,000/μL~* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.~* Patients with severe LV systolic dysfunction (LVEF\<25%) or in cardiogenic shock~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intracoronary abciximab (Type: ACTIVE_COMPARATOR): Intracoronary injection of bolus abciximab
- Aspiration thrombectomy (Type: ACTIVE_COMPARATOR): Aspiration thrombectomy
- Both use (Type: ACTIVE_COMPARATOR): Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Able to provide written informed consent prior to any study procedures.~* Diagnosis of Type 1 or 2 diabetic gastroparesis.~* Controlled Type 1 or 2 diabetes mellitus (HbA1c \<10.1%).~* Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to Period 1 (daily adjustments of insulin doses are permitted).~* Body mass index of 18-40 kg/m².~Key Exclusion Criteria:~* Unable or unwilling to provide informed consent or to comply with study procedures.~* History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure. (Note: history of diagnostic endoscopy is not exclusionary).~* Acute or chronic illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, poor renal or hepatic function, etc.~* Any clinically significant abnormalities on screening laboratories as determined by the Investigator.~* Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities or blood pressure at screening except minor deviations deemed to be of no clinical significance by the Investigator.~* Poor venous access or inability to tolerate venipuncture.~* Acute GI illness within 48 hours of Period 1.~* Positive pregnancy test.~* Participation in a clinical study within the 30 days prior to dosing in the present study.~* Any other reason, which in the opinion of the Investigator, would confound proper interpretation of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- RM-131 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Cholangiography During Cholecystectomy - a RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled for planned laparoscopic cholecystectomy by one surgeon~* Complicated gallstone disease~Exclusion Criteria:~* Open cholecystectomy~* Allergy towards iodine, urografin or indocyanine green~* Liver or renal insufficiency~* Thyrotoxicosis~* Pregnancy or lactation~* Legally incompetent for any reason~* Withdrawal of inclusion consent at any time

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescence cholangiography (Type: EXPERIMENTAL): After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
- X-ray cholangiography (Type: ACTIVE_COMPARATOR): The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients with essential hypertension~* Patients who are eligible and able to participate in the study~Exclusion Criteria~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health~* Subject's parent/legal guardian can read, understand, and complete the vaccine report card~* Subject is not sexually active and does not plan on becoming sexually active during the study~* Subject has received a documented full primary immunization series against diphtheria, tetanus, and pertussis (not in the last 5 years)~Exclusion Criteria:~* Subject has a known allergy to any vaccine component of V503, Menactra™, or Adacel™~* Subject has a condition that is a contraindication to vaccination with Menactra™ or Adacel™~* Subject has any coagulation disorder~* Female subject is pregnant~* Subject is immunocompromised or immunodeficient~* Subject has had a splenectomy~* Subject has received immunosuppressive therapies in the prior year~* Subject has received any immune globulin product or blood-derived product in the last 3 months~* Subject has received inactivated vaccines within 14 days or live vaccines within 21 days of the first study vaccination~* Subject has received a marketed HPV vaccine or has participation in an HPV vaccine trial~* Subject has received a meningococcal vaccine~* Subject has a fever \>= 100F within 24 hours of vaccination~* Subject has a history of HPV

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
- Non-concomitant Vaccination (Type: EXPERIMENTAL): V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Remineralizing Efficacy of Combination Varnishes on White Spot Lesions in ECC Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Preschool children with ECC.~2. Children with active white spot lesions on labial surface of 1 or more primary maxillary anterior teeth.~3. Children whose parents signed the informed consent form/willing to participate in the study.~4. Apart from fluoride varnish and fluoridated tooth paste, subjects exposed to no other form of fluoride were included.~Exclusion Criteria:~1. Preschool children with cavitated lesions on primary maxillary anterior teeth.~2. Developmental enamel alterations (hypoplasia, fluorosis).~3. Children with systemic diseases.~4. Children with allergy to milk products.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Profluorid group (Type: ACTIVE_COMPARATOR): 5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
- Enamel Pro (Type: EXPERIMENTAL): Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
- MI varnish (Type: EXPERIMENTAL): Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete